<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02376699</url>
  </required_header>
  <id_info>
    <org_study_id>SGNS40-001</org_study_id>
    <nct_id>NCT02376699</nct_id>
  </id_info>
  <brief_title>Safety Study of SEA-CD40 in Cancer Patients</brief_title>
  <official_title>A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety profile of SEA-CD40 given alone and in combination with
      pembrolizumab. The study will test increasing doses of SEA-CD40 given at least every 3 weeks
      to small groups of patients. The goal is to find the highest dose of SEA-CD40 that can be
      given to patients that does not cause unacceptable side effects. Different dose regimens will
      be evaluated. Different methods of administration may be evaluated. The pharmacokinetics,
      pharmacodynamic effects, biomarkers of response, and antitumor activity of SEA-CD40 will also
      be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in the following parts:

      Part A: Intravenous (IV) monotherapy dose-regimen finding for solid tumors --
      Dose-escalation, and possible dose-interval modification to lengthen the treatment cycle, to
      define the IV SEA-CD40 monotherapy maximum tolerated dose (MTD) and/or the optimal biological
      dose (OBD) regimens in patients with solid tumors. The ability to increase the dose intensity
      (to give additional doses within a treatment cycle) may be evaluated.

      Part B: IV monotherapy solid tumor expansion cohorts -- Disease-specific solid tumor
      expansion cohorts may be enrolled where patients will be treated with doses at or below the
      IV SEA-CD40 monotherapy MTD and/or OBD determined in Part A.

      Part C: IV monotherapy dose-regimen finding for lymphomas -- Dose-escalation, and possible
      dose-interval modification to lengthen the treatment cycle, to define the IV SEA-CD40
      monotherapy MTD and/or the OBD regimens in patients with lymphomas. The ability to increase
      the dose intensity (to give additional doses within a treatment cycle) may be evaluated.

      Part D: IV monotherapy lymphoma expansion cohorts -- Disease-specific lymphoma expansion
      cohorts may be enrolled where patients will be treated with doses at or below the IV SEA-CD40
      monotherapy MTD and/or OBD determined in Part C.

      Part E: Combination therapy dose-regimen finding for solid tumors -- IV SEA-CD40
      dose-escalation to define the MTD and/or the OBD regimen to be administered in combination
      with standard approved dose of pembrolizumab in patients with solid tumors.

      Part F: Combination therapy solid tumor expansion cohorts -- Disease-specific solid tumor
      expansion cohorts may be enrolled where patients will be treated with IV SEA-CD40 and
      pembrolizumab combination therapy; doses of SEA-CD40 will be at or below the MTD and/or OBD
      determined in Part E.

      Part G: Subcutaneous (SC) injection (injected under the skin) monotherapy dose-regimen
      finding for solid tumors -- Dose-escalation, and possible dose-interval modification to
      lengthen the treatment cycle, to define the SC SEA-CD40 monotherapy maximum tolerated dose
      (MTD) and/or the optimal biological dose (OBD) regimens in patients with solid tumors.

      Part H: SC monotherapy solid tumor expansion cohorts -- Disease-specific solid tumor
      expansion cohorts may be enrolled where patients will be treated with doses at or below the
      SC SEA-CD40 monotherapy MTD and/or OBD determined in Part G.

      (Note: There is no Part I)

      Part J: SC monotherapy dose-regimen finding for lymphomas -- Dose-escalation, and possible
      dose-interval modification to lengthen the treatment cycle, to define the SC SEA-CD40
      monotherapy MTD and/or the OBD regimens in patients with lymphomas.

      Part K: SC monotherapy lymphoma expansion cohorts -- Disease-specific lymphoma expansion
      cohorts may be enrolled where patients will be treated with doses at or below the SC SEA-CD40
      monotherapy MTD and/or OBD determined in Part J.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through up to approximately 6 weeks following last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of chemistry and hematology laboratory abnormalities</measure>
    <time_frame>Through up to approximately 6 weeks following last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of SEA-CD40</measure>
    <time_frame>Through up to approximately 6 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antitherapeutic antibodies against SEA-CD40</measure>
    <time_frame>Through up to approximately 6 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean absolute and percent change from baseline over time of selected pharmacodynamic markers</measure>
    <time_frame>Through up to approximately 6 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Through up to approximately 6 weeks following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Through up to approximately 6 weeks following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to approximately 6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Cancer</condition>
  <condition>Carcinoma</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Carcinoma, Squamous Cell</condition>
  <condition>Hematologic Malignancies</condition>
  <condition>Hodgkin Disease</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Lymphoma, Follicular</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Melanoma</condition>
  <condition>Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Neoplasms, Head and Neck</condition>
  <condition>Neoplasms, Squamous Cell</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Non-Small Cell Lung Cancer Metastatic</condition>
  <condition>Non-small Cell Carcinoma</condition>
  <condition>Squamous Cell Cancer</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <condition>Squamous Cell Neoplasm</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>IV Monotherapy in Solid Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Monotherapy in Lymphomas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy in Solid Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 (administered IV) + pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC Monotherapy in Solid Tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC Monotherapy in Lymphomas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEA-CD40 administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV SEA-CD40 monotherapy regimen</intervention_name>
    <description>Given intravenously on Day 1 every 3 weeks; or Days 1 and 8 every 3 weeks for 2 cycles, and then Day 1 every 3 weeks in subsequent cycles. Number of cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>IV Monotherapy in Solid Tumors</arm_group_label>
    <arm_group_label>IV Monotherapy in Lymphomas</arm_group_label>
    <arm_group_label>Combination Therapy in Solid Tumors</arm_group_label>
    <other_name>SEA-CD40</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Given intravenously on Day 2 every 3 weeks. Number of cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>Combination Therapy in Solid Tumors</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC SEA-CD40 monotherapy regimen</intervention_name>
    <description>Given intravenously on Day 1 every 3 weeks. Number of cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>SC Monotherapy in Solid Tumors</arm_group_label>
    <arm_group_label>SC Monotherapy in Lymphomas</arm_group_label>
    <other_name>SEA-CD40</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (Monotherapy - Parts A, B, C, D, G, H, J, and K) -- Histologically confirmed advanced
             malignancy, either: (a) Metastatic or unresectable solid malignancy; or (b) Classical
             Hodgkin lymphoma (HL), or diffuse large B-cell lymphoma (DLBCL), or indolent lymphoma
             (including follicular lymphoma [FL])

          -  (Monotherapy - Parts A, B, C, D, G, H, J, and K) -- Relapsed, refractory, or
             progressive disease, specifically: (a) Solid tumors: Following at least 1 prior
             systemic therapy, and no further standard therapy is available for the patient's
             advanced solid tumor at the time of enrollment; or (b) Classical HL: Following at
             least 2 prior systemic therapies in patients who are not candidates for autologous
             stem cell transplant (SCT), or following failure of autologous SCT; or (c) DLBCL:
             Following at least 1 prior systemic therapy; patients must have also received
             intensive salvage therapy unless they refused or were deemed ineligible; or (d)
             Indolent lymphoma: Following at least 1 prior chemoimmunotherapy regimen that included
             an anti-CD20 monoclonal antibody and for which no other more appropriate treatment
             option exists

          -  (Combination Therapy - Part E and Part F) -- Histologically confirmed advanced solid
             malignancy for which pembrolizumab treatment is approved

          -  Representative baseline tumor tissue sample is available

          -  Measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate baseline hematologic, renal, and hepatic function

          -  Recovery to Grade 1 of any clinically significant toxicity attributed to prior
             anticancer therapy prior to initiation of study drug administration

        Exclusion Criteria:

          -  Prior chemotherapy, small molecule inhibitors, radiation, and/or other investigational
             anticancer agents (excluding investigational monoclonal antibodies) within 2 weeks

          -  Prior immune-checkpoint inhibitors within 4 weeks (or 8 weeks, if immuno-oncology
             doublet used as the prior line of therapy)

          -  Prior monoclonal antibodies, antibody-drug conjugates, or radioimmunoconjugates within
             4 weeks (or 2 weeks if patient experienced disease progression on the prior treatment)

          -  Prior T-cell or other cell-based therapies within 12 weeks (or 2 weeks if patient
             experienced disease progression on the prior treatment)

          -  Recent or ongoing serious infections within 2 weeks

          -  Known positivity for hepatitis B infection

          -  Known active hepatitis C infection

          -  Active autoimmune or auto-inflammatory ocular disease within 6 months

          -  Known or suspected active organ-threatening autoimmune disease

          -  Active central nervous system tumor or metastases

          -  Patients with lymphomas: prior allogeneic SCT

          -  Patients in Part E or Part F: history of severe immune-mediated adverse reactions to
             pembrolizumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zejing Wang, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Schmitt, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seattle Genetics Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HOPE Line Patient Referral</last_name>
      <phone>205-996-4673</phone>
      <email>phase1referral@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Amitkumar Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HonorHealth Scottsdale Shea Medical Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandy Carothers</last_name>
      <phone>480-323-1323</phone>
      <email>brandy.carothers@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Michael Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosalinda Massie</last_name>
      <phone>310-967-4322</phone>
      <email>Rosalinda.Massie@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Monica Mita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Angeles Clinic and Research Institute, The</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saba Mukarram</last_name>
      <phone>310-231-2181</phone>
      <email>smukarram@theangelesclinic.org</email>
    </contact>
    <investigator>
      <last_name>Monica Mita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Nelson</last_name>
      <phone>312-942-8004</phone>
      <email>Patricia_Nelson@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Kuzel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Hoffman</last_name>
      <phone>773-834-7617</phone>
      <email>lhoffman2@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Gajewski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>University of Michigan Cancer Answer Line</last_name>
      <phone>800-865-1125</phone>
    </contact>
    <investigator>
      <last_name>David Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute / Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Salas</last_name>
      <phone>313-576-9816</phone>
      <email>salasc@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Heath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Minnesota</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Lensing</last_name>
      <phone>507-284-3137</phone>
      <email>lensing.janet@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Svetomir Markovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Zades</last_name>
      <phone>702-862-1104</phone>
      <email>christine.zades@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Fadi Braiteh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Cappadona</last_name>
      <phone>201-996-5900</phone>
      <email>Leah.Cappadona@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Martin Gutierrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwendolyn Boone</last_name>
      <phone>505-925-0356</phone>
      <email>GBoone@nmcca.org</email>
    </contact>
    <investigator>
      <last_name>Olivier Rixe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Ghalib</last_name>
      <phone>718-405-8515</phone>
      <email>mhghalib@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Sanjay Goel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center / University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Garbarino</last_name>
      <phone>984-974-8662</phone>
      <email>jennifer_garbarino@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Juneko Grilley-Olson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University / University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Information Services</last_name>
      <phone>800-641-2422</phone>
    </contact>
    <investigator>
      <last_name>David Bajor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Sutcliffe</last_name>
      <phone>503-215-5763</phone>
      <email>kimberly.sutcliffe@providence.org</email>
    </contact>
    <investigator>
      <last_name>Brendan Curti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Davis</last_name>
      <phone>713-792-3850</phone>
      <email>DLDavis@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Carolyn Hawkins</last_name>
      <phone>713-745-6784</phone>
      <email>chawkins@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Hun Ju Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance / University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SCCA Phase 1 Program</last_name>
      <phone>206-288-7551</phone>
      <email>Phase1@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Coveler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 30, 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD40 Antigen</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Hodgkin Disease</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Indolent Lymphoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Lymphoma, B-Cell</keyword>
  <keyword>Lymphoma, Large B-Cell, Diffuse</keyword>
  <keyword>Lymphoma, Non-Hodgkin</keyword>
  <keyword>Monoclonal Antibody</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasm Metastasis</keyword>
  <keyword>Solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

